Efficacy and safety of established and off‐label ADHD drug therapies for cognitive impairment or attention‐deficit hyperactivity disorder symptoms in bipolar disorder: A systematic review by the ISBD Targeting Cognition Task Force

Kamilla W. Miskowiak;Zacharias K. Obel;Riccardo Guglielmo;Caterina del Mar Bonnin;Christopher R. Bowie;Vicente Balanzá‐Martínez;Katherine E. Burdick;Andre F. Carvalho;Annemieke Dols;Katie Douglas;Peter Gallagher;Lars V. Kessing;Beny Lafer;Kathryn E. Lewandowski;Carlos López‐Jaramillo;Anabel Martinez‐Aran;Roger S. McIntyre;Richard J. Porter;Scot E. Purdon;Ayal Schaffer;Paul R. A. Stokes;Tomiki Sumiyoshi;Ivan J. Torres;Tamsyn E. Van ;Rheenen;Lakshmi N. Yatham;Allan H. Young;Eduard Vieta;Gregor Hasler

2024-01-01